[1] 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 肝纤维化诊断及治疗共识(2019年). 中华肝脏病杂志, 2019,27(9):657-667.
[2] EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol, 2015, 63(1): 237-264.
[3] Knodell R G, Ishak K G, Black W C, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology, 1981, 1(5): 431-435.
[4] Desmet V J, Gerber M, Hoofnagle J H, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology, 1994, 19(6): 1513-1520.
[5] Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol, 1995, 22(6): 696-699.
[6] Goodman Z D. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol, 2007, 47(4): 598-607.
[7] Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology, 1996, 24(2): 289-293.
[8] Tapper E B, Lok A S-F. Use ofliver imaging and biopsy in clinical practice. New Engl J Med, 2017, 377(8): 756-768.
[9] Lim J K, Flamm S L, Singh S, et al. American Gastroenterological Association Institute Guideline on therole of elastography in the evaluation of liver fibrosis. Gastroenterology, 2017, 152(6): 1536-1543.
[10] 中国肝炎防治基金会, 中华医学会感染病学分会, 中华医学会肝病学分会和中国研究型医院学会肝病专业委员会. 瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版). 中华肝脏病杂志, 2019, 27(3): 182-191.
[11] 张启迪, 陆伦根. 无创肝纤维化/肝硬化评估技术的现状. 中华肝脏病杂志, 2018, 26(5): 325-327.
[12] Bellan M, Castello L M, Pirisi M. Candidatebiomarkers of liver fibrosis: A concise, pathophysiology-oriented review. J Clin Transl Hepatol, 2018, 6(3): 317-325.
[13] Wai C T, Greenson J K, Fontana R J, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology, 38(2): 518-526.
[14] Richard K S. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (Baltimore, Md), 2006, 6(43):
[15] Forns X, Ampurdanes S, Llovet J M, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology, 2002, 36(4): 986-992.
[16] Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet, 2001, 357(9262): 1069-1075.
[17] Calès P, Oberti F, Michalak S, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology, 2005, 42(6): 1373-1381.
[18] Zeng M D, Lu L G, Mao Y M, et al. Prediction of significant fibrosis in HBeAg‐positive patients with chronic hepatitis B by a noninvasive model. Hepatology, 2005, 42(6): 1437-1445.
[19] Zhou K, Gao C F, Zhao Y P, et al. Simpler score of routine laboratory tests predicts liver fibrosis in patients with chronic hepatitis B. JGastroenterol Hepatol, 2010, 25(9): 1569-1577.
[20] Hui A Y, Chan H L-Y, Wong V W-S, et al. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol, 2005, 100(3): 616-623.
[21] Rosenberg W M, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology, 2004, 127(6): 1704-1713.
[22] Sud A, Hui J M, Farrell G C, et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology, 2004, 39(5): 1239-1247.
[23] Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology, 2007, 46(1): 32-36.
[24] Leroy V, Monier F, Bottari S, et al. Circulatingmatrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: Comparison with PIIINP and hyaluronic acid. Am J Gastroenterol, 2004, 99(2): 271-279.
[25] Lok A S, Ghany M G, Goodman Z D, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology, 2005, 42(2): 282-292.
[26] Islam S, Antonsson L, Westin J, et al. Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Hepatology, 2005, 42(7): 867-872.
[27] Fontana R J, Kleiner D E, Bilonick R, et al. Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. Hepatology, 2006, 44(4): 925-935.
[28] Koda M, Matunaga Y, Kawakami M, et al. FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology, 2007, 45(2): 297-306.
[29] Fontana R J, Goodman Z D, Dienstag J L, et al. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology, 2008, 47(3): 789-798.
[30] Adams L A, Bulsara M, Rossi E, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem, 2005, 51(10): 1867-1873.
[31] Patel K, Gordon S C, Jacobson I, et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol, 2004, 41(6): 0-942.
[32] Kelleher T B, Mehta S H, Bhaskar R, et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: The SHASTA index. 2005, 43(1):1-84.
[33] Angulo P, Hui J M, Marchesini G, et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology, 2007, 45(4): 846-854.
[34] Poynard T, Munteanu M, Imbert-Bismut F, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. ClinChem, 2004, 50(8): 1344-1355.
[35] Fraser J, Gibson P R. Mechanisms by which food intake elevates circulating levels of hyaluronan in humans.J Intern Med, 2005, 258(5): 460-466.
[36] Volpi N, Schiller J, Stern R, et al. Role, metabolism, chemical modifications and applications of hyaluronan. CurrMed Chem, 2009, 16(14): 1718-1745.
[37] Piton A, Poynard T, Imbert‐Bismut F, et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. Hepatology, 1998, 27(5): 1213-1219.
[38] Dong X Q, Wu Z, Zhao H, et al. Evaluation and comparison of thirty noninvasive models for diagnosing liver fibrosis in chinese hepatitis B patients. J Viral Hepat, 2019, 26(2): 297-307.
[39] Singh S, Muir A J, Dieterich D T, et al. American Gastroenterological Association Institute Technical Review on the role of elastography in chronic liver diseases. Gastroenterology, 2017, 152(6): 1544-1577.
[40] Sandrin L, Fourquet B, Hasquenoph J-M, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol, 2003, 29(12): 1705-1713.
[41] 曾静,范建高,爱肝联盟.弹性成像技术在慢性肝病诊断中应用的美国共识. 实用肝脏病杂志, 2018, 21(1): 32-33.
[42] Boursier J, Konate A, Guilluy M, et al. Learning curve and interobserver reproducibility evaluation of liver stiffness measurement by transient elastography. Eur J Gastroenterol Hpatol, 2008, 20(7): 693-701.
[43] Jia J, Hou J, Ding H, et al. Transient elastography compared to serum markers to predict liver fibrosis in a cohort of Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol, 2015, 30(4): 756-762.
[44] Chen Y P, Liang X E, Dai L, et al. Improving transient elastography performance for detecting hepatitis B cirrhosis. Dig Liver Dis, 2012, 44(1): 61-66.
[45] Chen Y P, Liang X E, Zhang Q, et al. Larger biopsies evaluation of transient elastography for detecting advanced fibrosis in patients with compensated chronic hepatitis B. J Gastroenterol Hepatol, 2012, 27(7): 1219-1226.
[46] Afdhal N H, Bacon B R, Patel K, et al. Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. Clin Gastroenterol Hepatol, 2015, 13(4): 772-779 e771-773.
[47] Seo Y S, Kim M Y, Kim S U, et al. Accuracy of transient elastography in assessing liver fibrosis in chronic viral hepatitis: A multicentre, retrospective study. Liver Int, 2015, 35(10): 2246-2255.
[48] Siddiqui M S, Vuppalanchi R, Van Natta M L, et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol, 2019, 17(1): 156-163 e152. |
